Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 7/2017

27.05.2017 | Review

Novel and Experimental Therapies in Chronic Pancreatitis

verfasst von: Soumya Jagannath, Pramod Kumar Garg

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Chronic pancreatitis (CP) is a progressive inflammatory disease of the pancreas. The currently available treatment of CP is aimed at controlling symptoms and managing complications. Unfortunately, no specific treatment is available to halt the progression of the disease process because the pathophysiological perturbations in CP are not well understood. In this review, we discuss various therapeutic targets and investigational agents acting on these targets. Among these, therapies modulating immune cells and those acting on pancreatic stellate cells appear promising and may translate into clinical benefit in near future. However, these experimental therapies are mostly in animal models and they do not recapitulate all aspects of human disease. Still they may be beneficial in developing effective therapeutic modalities to curb inflammation in chronic pancreatitis.
Literatur
1.
Whitcomb DC, Frulloni L, Garg P, Greer JB, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. Pancreatology. 2016;16:218–224.CrossRefPubMed
2.
The Copenhagen Pancreatic Study Group. An interim report from a prospective epidemiological multicentre study. Scand J Gastroenterol. 1981;16:305–312.CrossRef
3.
Robles-Diaz G, Vargas F, Uscanga L, Fernandez-del Castillo C. Chronic pancreatitis in Mexico City. Pancreas. 1990;5:479–483.CrossRefPubMed
4.
Garg PK, Tandon RK. Survey on chronic pancreatitis in the Asia-Pacific region. J Gastroenterol Hepatol. 2004;19:998–1004.CrossRefPubMed
5.
Lin Y, Tamakoshi A, Matsuno S, Takeda K, et al. Nationwide epidemiological survey of chronic pancreatitis in Japan. J Gastroenterol. 2000;35:136–141.CrossRefPubMed
6.
Balaji LN, Tandon RK, Tandon BN, Banks A. Prevalence and clinical features of chronic pancreatitis in southern India. Int J Pancreatol. 1994;15:29–34.PubMed
7.
Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120:682–707.CrossRefPubMed
8.
Tandon RK, Sato N, Garg PK. Chronic pancreatitis: Asia-Pacific consensus report. J Gastroenterol Hepatol. 2002;17:508–518.CrossRefPubMed
9.
Rösch T, Daniel S, Scholz M, Huibregtse K, European Society of Gastrointestinal Endoscopy Research Group. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up. Endoscopy. 2002;34:765–771.CrossRefPubMed
10.
Cahen DL, Gouma DJ, Nio Y, Rauws EJ, et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. N Engl J Med. 2007;356:676–684.CrossRefPubMed
11.
Xue J, Sharma V, Habtezion A. Immune cells and immune-based therapy in pancreatitis. Immunol Res. 2014;58:378–386.CrossRefPubMed
12.
Zimnoch L, Szynaka B, Puchalski Z. Mast cells and pancreatic stellate cells in chronic pancreatitis with differently intensified fibrosis. Hepatogastroenterology. 2002;49:1135–1138.PubMed
13.
Schmitz-Winnenthal H, Pietsch DH, Schimmack S, Bonertz A, et al. Chronic pancreatitis is associated with disease-specific regulatory T-cell responses. Gastroenterology. 2010;138:1178–1188.CrossRefPubMed
14.
Grundsten M, Liu GZ, Permert J, Hjeilmstrom P, Tsai JA. Increased central memory T cells in patients with chronic pancreatitis. Pancreatology. 2005;5:177–182.CrossRefPubMed
15.
Marrache F, Pendyala S, Bhagal G, Betz KS, Song Z, Wang TC. Role of bone marrow derived cells in experimental chronic pancreatitis. Gut. 2008;57:1113–1120.CrossRefPubMed
16.
Lardon J, Rooman I, Bouwens L. Nestin expression in pancreatic stellate cells and angiogenic endothelial cells. Histochem Cell Biol. 2002;117:535–540.CrossRefPubMed
17.
18.
Xue J, Sharma V, Hsieh MH, Chawla M, et al. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. Nature communications. 2015;6:7158.CrossRefPubMedPubMedCentral
19.
Baumert J-T, Sparmann G, Emmrich J, Stefan L, Jaster R. Inhibitory effect of interferons on pancreatic stellate cell activation. World J Gastroenterol. 2006;12:896–901.CrossRefPubMedPubMedCentral
20.
Zhao HF, Ito T, Gibo J, Kawabe K, et al. Anti-monocyte chemoattractant protein 1 gene therapy attenuates experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Gut. 2005;54:1759–1767.CrossRefPubMedPubMedCentral
21.
Su SB, Xie MJ, Sawabu N, Motoo Y. Supressive effect of herbal medicine Saiko-Keishi-to on acinar cell apoptosis in rat spontaneous chronic pancreatitis. Pancreotology. 2007;7:28–36.CrossRef
22.
Su SB, Motoo Y, Xie MJ, Taga H, Sawabu N. Antifibrotic effect of herbal medicine Saiko-Keishi-to (TJ-10) on chronic pancreatitis in the WBN/KOB rat. Pancreas. 2001;22:8–17.CrossRefPubMed
23.
Masamune A, Suzuki N, Kikuta K, Satoh M, Satoh K, Shimosewaga T. Curcumin blocks activation of pancreatic stellate cells. J Cell Biochem. 2006;95:1080–1093.CrossRef
24.
Wei L, Yamamoto M, Harada M, Otsuki M. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. Lab Invest. 2011;91:872–884.CrossRefPubMed
25.
Jaster R, Brock P, Sparmann G, Emmrich J, Liebe S. Inhibition of pancreatic stellate cell activation by the hydroxymethylglutaryl coenzyme A reductase inhibitor Lovastatin. Biochem Pharmacol. 2003;65:1295–1303.CrossRefPubMed
26.
27.
Kuno A, Yamada T, Masuda K, Ogawa K, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology. 2003;124:1010–1019.CrossRefPubMed
28.
Skipworth JR, Nijmeijer RM, van Santvoort HC, Besselink MG, et al. The effect of renin angiotensin system genetic variants in acute pancreatitis. Ann Surg. 2015;261:180–188.CrossRefPubMed
29.
Madro A, Kurzepa J, Celinski K, Slomka M, et al. Effects of renin-angiotensin system inhibitors on fibrosis in patients with alcoholic chronic pancreatitis. J Physiol Pharmacol. 2016;67:103–110.PubMed
30.
Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase. Biochim Biophys Acta Enzymol. 1977;484:417–422.CrossRef
31.
Gibo J, Ito T, Kawabe K, Hisano T, et al. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Inv. 2005;85:75–89. CrossRef
32.
Otsuki M, Okhi A, Okabayashi Y, Suehiro I, Baba S. Effect of synthetic protease inhibitor camostat on pancreatic exocrine function in rats. Pancreas. 1987;2:164–169.CrossRefPubMed
33.
Kisfalvi K, Papp M, Friess H, Buchler M, Goracz UG. Beneficial effects of oral administration of camostat on cerulein-induced pancreatitis in rats. Dig Dis Sci. 1995;40:546–547.CrossRefPubMed
34.
Ito T, Otsuki M, Itoi T, Shimosegawa T, et al. Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan. J Gastroenterol. 2007;42:291–297.CrossRefPubMed
35.
Jaster R, Hilgendorf I, Fitzner B, Brock P, et al. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochem Pharmacol. 2003;66:633–641.CrossRefPubMed
36.
Li XC, Lu XL, Chen HH. α-Tocopherol treatment ameliorates chronic pancreatitis in an experimental rat model induced by trinitrobenzene sulfonic acid. Pancreatology. 2011;11:5–11.CrossRefPubMed
37.
Yoo BM, Oh TY, Kim YB, Yeo Y, et al. Novel antioxidant ameliorates the fibrosis and inflammation of cerulein-induced chronic pancreatitis in a mouse model. Pancreatology. 2005;5:165–176.CrossRefPubMed
38.
Mrazek AA, Porro LJ, Bhatia V, Falzon M, et al. Apigenin inhibits pancreatic stellate cell activity in pancreatitis. J Surg Res. 2015;196:8–16.CrossRefPubMedPubMedCentral
39.
Suzuki N, Masamune A, Kikuta K, Watanabe T, Satoh K, Shimosegawa K. Ellagic acid inhibits pancreatic fibrosis in male Wistar Bonn/Kobori rats. Dig Dis Sci. 2009;54:802–810.CrossRefPubMed
40.
Masamune A, Kikuta K, Satoh M, Suzuki N, Shimosewaga T. Green tea polyphenol epigallocatechin-3-gallate blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells. World J Gastroenterol. 2005;11:3368–3374.CrossRefPubMedPubMedCentral
41.
Asaumi H, Wantabe S, Taguchi M, et al. Green tea polyphenol (-) -epigallocatechin-3-gallate inhibits ethanol induced activation of pancreatic stellate cells. Eur J Clin Invest. 2006;36:113–122.CrossRefPubMed
42.
Jaster R, Sparmann G, Emmrich J, Liebe S. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. Gut. 2002;51:579–584.CrossRefPubMedPubMedCentral
43.
Lin Z, Zheng LC, Zhang HZ, Tsang SW, Bian ZX. Antifibrotic effects of phenolic compounds on pancreatic stellate cells. BMC Complement Altern Med. 2015;15:259.CrossRefPubMedPubMedCentral
44.
Zion O, Genin O, Kawada N, Yoshizato K, et al. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas. 2009;38:427–435.CrossRefPubMed
45.
Niina Y, Ito T, Oono T, Nakamura T, Fujimori N, et al. A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology. 2014;14:201–210.CrossRefPubMed
46.
Reding T, Bimler D, Perren A, Sun LK, et al. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. Gut. 2006;55:1165–1173.CrossRefPubMedPubMedCentral
47.
Wei L, Yamamoto M, Harada M, Otsuki M. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. Lab Inv. 2011;91:872–884.CrossRef
48.
Zhou CH, Lin-Li, Zhu XY, Wen-Tang, et al. Protective effects of edaravone on experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology. 2013;13:125–132.CrossRefPubMed
49.
Yang T, Liang Y, Lin Q, Liu J, et al. miR-29 mediates TGF β1-induced extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung fibroblasts. J Cell Biochem. 2013;114:1336–1342.CrossRefPubMed
50.
Xiong M, Jiang L, Zhou Y, Qiu W, et al. The miR- 200 family regulates TGF-b1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2012;302:F369–F379.CrossRefPubMed
51.
Zhu H, Luo H, Li Y, Zhou Y, et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol. 2013;33:1100–1109.CrossRefPubMed
52.
Zarjou A, Yang S, Abraham E, Agarwal A, Liu G. Identification of a micro RNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol. 2011;301:F793–F801.CrossRefPubMedPubMedCentral
53.
Chan LK, Gerstenlauer M, Konukiewitz B, Steiger K, et al. Epithelial NEMO/IKKγ limits fibrosis and promotes regeneration during pancreatitis. Gut 2016. doi:10.​1136/​gutjnl-2015-311028.
54.
Midha S, Hasan A, Dhingra R, Garg PK. Long-term pain relief with optimized medical including antioxidants and step-up interventional therapy in patients with chronic pancreatitis. J Gastroenterol Hepatol. 2016;32:270–277. doi:10.​1111/​jgh.​13410.
55.
Garg PK. Antioxidants for chronic pancreatitis: reasons for disappointing results despite sound principles. Gastroenterology. 2013;144:e19–e20.CrossRefPubMed
56.
Tang Y, Laio Y, Kawaguchi-Sakita N, Raut V, et al. Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats. J Hepatobiliary Pancreat Sci. 2011;18:551–558.CrossRefPubMed
57.
Shiratori K, Takeuchi T, Satake K, Matsuno S. Clinical evaluation of oral administration of a cholecystokinin A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose response study in Japan. Pancreas. 2002;25:e15.CrossRef
58.
Levenick JM, Andrews CL, Purich ED, Gordon SR, Gardner TB. A phase II trial of human secretin infusion for refractory type B pain in chronic pancreatitis. Pancreas. 2013;42:596–600.CrossRefPubMed
59.
Zhang L, Kline RH, McNearney TA, Johnson MP, Westlund KN. Cannabinoid receptor 2 agonist attenuates pain related behavior in rats with chronic alcohol/high fat diet induced pancreatitis. Mol Pain. 2014;10:66.CrossRefPubMedPubMedCentral
60.
Wang Y, Li Y, Wang L, Kang Y, et al. Tanshinone IIA attenuates chronic pancreatitis- induced pain in rats via downregulation of HMGB1 and TRL4 expression in the spinal cord. Pain Phys. 2015;18:E615–E628.
61.
Ceppa E, Cattaruzza F, Lyo V, Amadesi S, et al. Transient receptor potential ion channels V4 and A1 contribute to pancreatitis pain in mice. Am J Physiol Gastrointest Liver Physiol. 2010;299:G556–G571.CrossRefPubMedPubMedCentral
62.
Zhang LP, Ma F, Abshire SM, Westlund KN. Prolonged high fat/alcohol exposure increases TRPV4 and its functional responses in pancreatic stellate cells. Am J Physiol Regul Integr Comp Physiol. 2013;304:R702–R711.CrossRefPubMedPubMedCentral
63.
Zhang LP, Kline RH, Deevska IG, Ma F, et al. Alcohol and high fat induced chronic pancreatitis: TRPV4 antagonist reduces hypersensitivity. Neuroscience. 2015;311:166–179.CrossRefPubMedPubMedCentral
64.
Kapural L, Cywinski JB, Sparks DA. Spinal cord stimulation for visceral pain from chronic pancreatitis. Neuromodulation. 2011;14:423–427.CrossRefPubMed
65.
Midha S, Khajuria R, Shastri S, Kabra M, Garg PK. Idiopathic chronic pancreatitis in India: phenotypic characterization and strong genetic susceptibility due to SPINK1 and CFTR gene mutations. Gut. 2010;59:800–807.CrossRefPubMed
66.
Van Goor F, Hadida S, Grootenhuis PD, Burton B, et al. Correction of the F508delCFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108:18843–18848.CrossRefPubMedPubMedCentral
67.
Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA. 2013;110:4404–4409.CrossRefPubMedPubMedCentral
68.
Hayes D Jr, McCoy KS, Sheikh SI. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med. 2014;190:590–591.CrossRefPubMed
69.
Bellin MD, Laguna T, Leschyshyn J, Regelmann W, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes. 2013;14:417–421.CrossRefPubMedPubMedCentral
70.
Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91.CrossRefPubMed
71.
Alton EW, Armstrong DK, Ashby D, Bayfield KJ, et al. UK Cystic Fibrosis Gene Therapy Consortium. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebocontrolled, phase 2b trial. Lancet Respir Med. 2015;3:684–691.CrossRefPubMedPubMedCentral
72.
Zhou CH, Li ML, Qin AL, Lv SX, et al. Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton’s jelly. Pancreas. 2013;42:1291–1302.CrossRefPubMed
Metadaten
Titel
Novel and Experimental Therapies in Chronic Pancreatitis
verfasst von
Soumya Jagannath
Pramod Kumar Garg
Publikationsdatum
27.05.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2017
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4604-0

Weitere Artikel der Ausgabe 7/2017

Digestive Diseases and Sciences 7/2017 Zur Ausgabe

Review

Surgical Management of Pancreatic Cysts: A Shifting Paradigm Toward Selective Resection

Review

Endoscopic Management of Pancreatic Cysts

Review

Insights into the Pathogenesis of Pancreatic Cystic Neoplasms

Review

Autoimmune Pancreatitis

Review

Imaging Pancreatic Cysts with CT and MRI

Editorial

Editors’ Introduction to the Chronic Pancreatitis and Pancreatic Cysts Special Issue

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise